Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

The investigators noted cardiovascular events for up to 1 year post-discharge in 18.5% of RSV patients, compared with 17.7% ...

Hidden in the lungs of some breast cancer survivors are tumour cells that can remain dormant for decades — until they one day ...